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INfLUENcE Of TRImETAZIdINE mETABOLIc ThERAPY ON cONNEcTIVE 
TIssUE mETABOLIsm IN EXPERImENTAL dIffUsE IschEmIc NEcROTIc 
cARdIOscLEROsIs IN RATs WITh dIffERENT RATEs Of hYPOXIA 
REsIsTANcE
H. S. Saturska, Yu. І. Bondarenko, U. V. Saturska
I. HORBACHEVSKY TERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
Background. The change in metabolism of the connective tissue elements of heart is the central chain in 
pathogenesis of diffuse ischemic necrotic cardiosclerosis (DINC), which occurs after repeated epinephrine injury 
of myocardial tissues.
Objective. This study proves that trimetazidine (TM) metabolic therapy has a protective effect on the 
development of DINC in rats with different rates of hypoxia resistance. 
Methods. Male white rats were divided into three groups due to the different rates of hypoxia resistance by 
means of the method of hypobaric hypoxia: rats with low, middle and high rates of hypoxia resistance. Each 
group was divided into equal subgroups: a control group, a DINC group (injections of epinephrine hydrotartrate 
(0,5 mg/kg of body weight) and calcium gluconate (5 mg/kg of body weight) two times), a control group admin-
istrated with trimetazidine dihydrochloride (10 mg/kg of body weight), a DINC group treated with TM every day 
(10 mg/kg of body weight) for all period of observation. Concentration of protein-bound oxyproline in blood 
serum was evaluated on the 7th, 14th and 30th days after the pathology simulation. Histological examination of 
Masson trichrome staining of myocardium was performed on the 30th days after the pathology simulation. 
Results. DINC increased the concentration of protein-bound oxyproline in blood serum on the 7th, 14th and 
30th days after the pathology simulation, and followed by metabolic imbalances in diffuse connective tissue ele-
ments, which are rich in collagens. DINC+TM increased the concentration of protein-bound oxyproline in blood 
serum less intensively.
Conclusions. The intensity of metabolic imbalances in diffuse connective tissue elements is the highest in 
the low resistant animals to hypoxia. Those results are confirmed by histological examination of the myocardium 
of rats with different resistance to hypoxia. Fibrotic regions in myocardium are rich in collagens. It has been 
revealed that the most pronounced therapeutic effect of TM is observed in animals with low resistance to hypoxia, 
slight – in animals with medium resistance to hypoxia, and the lowest – in animals with high resistance to 
hypoxia.
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Introduction
The pathology of the cardiovascular system 
is the major medical and social problem, 
because it takes the main cause of morbidity 
and mortality [1-2]. The special attention is paid 
to the research on diagnostic markers of degra-
dation and reparation of myocardial tissue 
[3-5], which would reflect the dynamic changes 
in myocardium and were predictors of diffuse 
cardiosclerosis [2-3]. The purpose of this inves-
tigation was to determine the changes in the 
content of protein-bound oxyproline in blood 
as a diagnostic marker of metabolic activity of 
collagen at the experimental diffuse ischemic 
necrotic cardiosclerosis in rats with different 
rate of hypoxia resistance. 
Recently, we demonstrated that the use of 
trimetazidine as an endogenous cardioprotection 
inducer in the development of diffuse ischemic 
necrotic cardiosclerosis is manifested by de-
crease in manifestations of oxidative and 
nitrooxidative stress, optimization of immune 
and cytokinе response, stabilization of humoral 
immune responsiveness [6]. The research was 
carried out to study the effects of TM on the 
improvement of connective tissue elements 
metabolism, indicating inhibition of cardio-
sclerotic process.
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Materials and Methods 
Animals and treatment 
Experiments were done on 192 male white 
rats (190-250 g) of the vivarium of Ternopil State 
Medical University, Ukraine. All animals re-
ceived care in compliance with the “Guide for 
Care and Use of Laboratory Animals” (National 
Institute of Health Publication № 85-23, revised 
1985). The studies were carried out according 
to the National Institute of Health Guide for 
Care and Use of Laboratory Animals and were 
approved by the local animal protection com-
mittee. 
The experimental animals were divided into 
three groups according to different rates of 
hypoxia resistance by means of the method of 
hypobaric hypoxia [6] [Berezovskyi, 1975; Mar-
kova, 1998]: rats with low, middle and high rates 
of hypoxia resistance. Each group was divided 
into equal subgroups: a control group, a diffuse 
ischemic necrotic cardiosclerosis group (injec-
tions of epinephrine hydrotartrate (0,5 mg/kg 
body weight) and calcium gluconate (5 mg/kg 
of body weight) two times), a control group 
administered with trimetazidine dihydrochlo-
ride (10 mg/kg of body weight) every day [6], 
diffuse ischemic necrotic cardiosclerosis group 
treated with trimetazidine dihydrochloride (10 
mg/kg of body weight) every day for all period 
of observation (n=8 of each group). 
Evaluation of protein-bound oxyproline in 
blood serum 
Concentration of protein-bound oxyproline 
in blood serum was determined biochemically 
[7] on the 7th, 14th and 30th days after the pathol-
ogy simulating. 
Histopathology study 
The tissue from myocardium ventricles was 
taken on the 30th day after pathology simula-
tion, then put in 10 % neutral-buffered formalin 
solution for 5 days, embedded in paraffin, and 
sectioned. Histological examination of Masson 
trichrome staining of myocardium was per-
formed [8]. 
Statistical analysis 
Statistical analysis was carried out by Orig-
inPro Program. The results were presented as 
mean±standard deviation. Differences between 
experimental groups were analyzed with an 
unpaired two-tailed Student t-test [9]. Values 
were considered to be statistically significant 
at p<0.05.
Results 
Before the DINC simulation the protein-
bound oxyproline concentration in blood serum 
of rats with low hypoxia resistance was 17.8% 
(p<0.05) higher than in blood serum of rats with 
middle hypoxia resistance (Table 1), oxyproline 
concentration in blood serum of high hypoxia 
resistant animals was 21.9% lower (p<0.05) than 
in blood serum of rats with middle hypoxia 
resistance. After the DINC simulation protein-
bound oxyproline concentration in blood serum 
of rats gradually increased at all groups. 
Under the influence of trimetazidine meta-
bolic therapy the changes in protein-bound 
oxyproline concentrations in blood serum of 
the animals with low hypoxia resistance were 
less pronounced (Table 2). Concentration of this 
metabolite collagen in 7 days after pathology 
simulation with TM was by 11.0% (p<0.05) 
(Figure 1) lower than in the group of untreated 
animals at this stage of observation. On the 14th 
day after DINC simulation with TM, protein-
bound oxyproline concentration in blood serum 
of the rats with low hypoxia resistance was by 
25.3% lower (p<0.001) than in the untreated 
animals, and on the 30th day of observation it 
was by 33.9% (p<0.001) lower than in the 
Table 1. Protein-bound oxyproline concentration in blood serum in cases of experimental diffuse 
ischemic necrotic cardiosclerosis (DInC) with innate hypoxia resistance in rats 
Hypoxia resistance 
rate in animals 
Control group
(n=8)
Stages of DINC observation 
7 days
(n=8)
14 days
(n=8)
30 days
(n=8)
Low 49,55±0,59 
р<0,05
57,45±1,78
р<0,01
р*<0,01
79,15±2,66
р<0,01
р*<0,01
104,84±3,42
р<0,01
р*<0,01
Middle 42,07±1,10 47,92±0,62
р*<0,01
58,24±1,00
р*<0,01
73,38±3,30
р*<0,01
High 34,52±0,92
р<0,05
38,53±0,55
р<0,01
р*<0,05
42,65±1,19
р<0,01
р*<0,01 
56,43±2,84 
р<0,01
р*<0,01 
Notes: p<0.05 – significantly different from middle hypoxia resistant animals at all stages of observation; *р<0.05 – 
significantly different from the control group at all stages of observation.
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untreated animals with low hypoxia resistance 
at the similar stage of cardiosclerotic process 
development without any correction.
In blood serum of the rats with middle 
hypoxia resistance, protein-bound oxyproline 
concentration on the 7th day after DINC simu-
lation and trimetazidine correction was by 8.3% 
(p<0.05) (Fig. 1) lower than in the group of un-
treated animals at this stage of observation. At 
the next stage of observation, on the 14th day 
of DINC simulation, protein-bound oxyproline 
concentration in blood serum of these animals 
was by 18.6% lower (p<0.001) than in the 
untreated ones, and on the 30th day of DINC 
observation – by 28.2% (p<0.001) lower than in 
the untreated rats.
There was no significantly difference bet-
ween the treated and untreated animals with 
high hypoxia resistance on the 7th day of DINC 
observation. On the 14th day after the pathology 
simulation, protein-bound oxyproline concen-
tration was lower by 11.6% (p<0.05) than in the 
group of untreated animals at this stage of 
observation; and on the 30th day of DINC 
observation and correction with metabolic the-
rapy, concentration of protein-bound oxyproline 
in blood serum was 28.4% (p<0.001) lower than 
in the untreated animals with high hypoxia 
resistance without any correction.
Histological examination of the myocardium 
on the 30th day of DINC observation showed 
that at heart micropreparations of the healthy 
animals with different rates of hypoxia resis-
tance, connective tissue was observed slightly 
in the form of thin collagen fibers (Figure 2), 
but in heart micropreparations of the animals 
with DINC (Figure 3) focal cardiosclerosis, 
perivascular sclerosis hyperelasticity of vessels 
Table 2. Influence of trimetazidine on protein-bound oxyproline concentration in blood serum in 
cases of experimental diffuse ischemic necrotic cardiosclerosis (DInC) with innate hypoxia 
resistance in rats 
Hypoxia resistance 
rate in animals
Control TM group
(n=8)
Stages of DINC+TM observation
7 days
(n=8)
14 days
(n=8)
30 days
(n=8)
Low 45,58±1,51 51,15±1,36
р*<0,05
р<0,001
59,09±1,85
р*<0,001
р<0,001
69,32±1,86
р*<0,001
р<0,001
Middle 40,58±1,83 43,97±1,34 40,58±1,83
р*<0,05
52,72±3,15
р*<0,05
High 34,90±0,96
р<0,05
36,33±0,91
р<0,001
37,72±1,52
р<0,001 
34,90±0,96 
р*<0,05
р<0,01 
Notes: p<0.05 – significantly different from the middle hypoxia resistant of animals at all stages of observation;
*р<0.05 – significantly different from the control group at all stages of observation.
Fig. 1. Influence of trimetazidine on protein-bound oxyproline concentration in blood serum in cases of experimental 
diffuse ischemic necrotic cardiosclerosis (DINC) with innate hypoxia resistance in rats.
Notes: the indices of the control groups were presented in 100%; * – significantly different from the control group at all 
stages of observation, p<0.05; # – significantly different from the untreated rats at all stages of observation, p<0.05. 
0
50
100
150
200
250
Control DINC 7 days DINC 14 days DINC 30 days
LRH LRH+TM MRH MRH+TM HRH HRH+TM
%
*
*
* *
*
*
*
**
#
#
#
#
#
#
###
 
H. S. Saturska et al.
52
b
IO
M
Ed
Ic
A
L 
Sc
IE
N
cE
S
ISSN 2413-6077. IJMMR 2016 Vol. 2 Issue 1
Discussion
Evaluation of protein-bound oxyproline 
concentrations in blood serum in DINC simu-
lation with and without trimetazidine correction 
proved that increased collagen production and 
products of its metabolism [4-5] can be used as 
a biological marker of the intensity of collagen 
synthesis in tissue infarction. So we can make 
the following conclusion: the intensity of 
metabolic imbalance of connective elements in 
cases of diffuse ischemic necrotic cardiosclerosis 
and trimetazidine correction depends on hy-
poxia resistance of animals. In the low hypoxia 
resistance animals, maximum effect of trime-
tazidine correction was manifested; however, 
more pronounced changes in oxyproline 
concentration were in DINC simulation without 
any correction. This effect was not enough for 
denoting differences between animals with 
different rates of hypoxia resistance. This 
matter is characteristic feature of animals with 
middle hypoxia resistance, but the changes 
were less pronounced. Animals with high 
hypoxia resistance were characterized by lower 
oxyproline concentration, which changed after 
DINC simulation, so the effect was manifested 
less, but in general, they are characterized by 
minimal metabolic disorders of connective 
tissue elements in the development of DINC 
and correction with trimetazidine [10-16]. The 
activity of connective tissue metabolism was 
studied in experimental diffuse ischemic ne cro-
tic cardiosclerosis with different rates hy poxia 
resistance of a body. The investigations were 
based on the changes in concentration of pro-
tein-bound oxyproline in blood serum that 
pro ved adequate metabolic changes in collagen 
[4–5].
Conclusions
The development of the experimental 
diffuse ischemic necrotic cardiosclerosis at all 
stages of observation was accompanied by 
metabolic imbalance in connective tissue of 
heart, and was proved by the increase in 
oxyproline level in blood serum of animals with 
different rates of hypoxia resistance. The inten-
sity of metabolic imbalances in diffuse connec-
tive tissue elements was the highest in low 
hypoxia resistant animals. Those results were 
confirmed by histological examination of myo-
cardium of rats with different rates of hypoxia 
resistance. Fibrotic regions in myocardium are 
rich in collagens. It has been revealed that the 
most pronounced therapeutic effect of TM is 
observed in animals with low hypoxia resistance, 
Fig. 2. Myocardium of the control rat. Masson trichrome 
staining of myocardium. х 400. 
Fig. 3. Myocardium of the low hypoxia resistant rat with 
DINC. Fibrotic regions in myocardium are rich in collagens 
and therefore appear in blue upon Masson trichrome 
staining. In addition, centralized nuclei as well as shape 
and size distribution of myofibers were detected that was 
the evidence of pronounced cardiomyocytes hypertrophy. 
30-day DINC. Masson trichrome staining of myocardium. 
х400.
inner membrane, cardiomyocyte hypertrophy, 
diffuse proliferation of connective tissue were 
presented. Fibrotic regions in myocardium are 
rich in collagens and therefore appear in blue 
upon Masson trichrome staining. In addition, 
centralized nuclei as well as shape and size 
distribution of myofibers were detected that 
was the evidence of pronounced cardiomyocytes 
hypertrophy.
All the above-mentioned symptoms are the 
highest in the low hypoxia resistant animals, 
indicating the intense development of diffuse 
cardiosclerosis in animals with low hypoxia 
resistance and confirm the results obtained 
during evaluation of the concentration of 
protein-bound oxyproline serum of rats with 
different rates of hypoxia resistance.
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slightly less – in animals with medium hypoxia 
resistance, and the lowest – in animals with high 
hypoxia resistance. This matter was evidenced 
at all stages of observation, but it was the most 
pronounced in the early period of cardiosclerotic 
process, indicating the feasibility of early use 
of metabolic therapy. It explains the absence 
of cardioprotective effect of trimetazidine in the 
later stages of cardiosclerosis, when the 
myocardial fibrosis is already formed.
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